Safety, tolerability, pharmacokinetic, pharmacodynamic and immunogenicity profiles of Exendin‐4‐IgG4‐Fc in healthy subjects: A phase 1, single‐centre, randomized, double‐blind, dose escalation study

Documenti analoghi

• First‐Year IgG Dynamics in IgG4 ‐Related Disease: A Critical Window for Predicting Long‐Term Outcomes
  di: Xin He, et al.
  Pubblicazione: (2026)
• Phase I study of the oral GLP ‐1 receptor agonist DA ‐ 302168S : Safety, pharmacokinetics, and pharmacodynamics in healthy and overweight/obese adults
  di: Liang Zheng, et al.
  Pubblicazione: (2025)
• Safety, tolerability, pharmacokinetics, pharmacodynamics and food effect of HRS‐1893, a cardiac myosin inhibitor, in healthy subjects
  di: Kexu Yang, et al.
  Pubblicazione: (2026)
• Pharmacokinetics, pharmacodynamics, and safety of frunexian in healthy Chinese volunteer adults: A randomized dose‐escalation phase I study
  di: Jia‐yu Zhang, et al.
  Pubblicazione: (2024)
• Allergen‐Specific IgE and IgG4 Signatures in IgG4 ‐Related Disease Revealed by a Large‐Scale PhIP ‐Seq Study
  di: Zhan Li, et al.
  Pubblicazione: (2025)